Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

European Medicines Agency

EMA to scale back work further after Christmas because of Brexit relocation

As Brexit looms, the European Medicines Agency will be paring down its operations further in January 2019.

The EMA's new building in Amsterdam

Source: Amsterdam EMA bid

As it relocates to Amsterdam (new offices pictured), the European Medicines Agency’s scaling back of operations is expected to last until 30 June 2019, but a decision will be taken in April 2019 on when a full programme of work can resume

The European Medicines Agency (EMA) has warned that it will have to cut down its work even further as it relocates from London to Amsterdam because of Brexit.

Announcing the introduction of the third phase of its plan to focus on core work during the run-up to Brexit, the EMA said it would have to pare down its operations even further in January 2019.

Phase three of the EMA’s ‘Brexit preparedness business continuity plan’ kicked in on 1 October 2018, but it said that it “anticipates that phase three will have to be complemented with additional temporary suspensions/reductions as of 1 January 2019”.

The latest scaling back of work includes slowing down on guideline development and revision. The EMA is also expected to put non-product related working parties on hold from 1 November 2018.

But the EMA said it would continue to work on seven guidelines that either address an urgent public or animal health need, or are related to Brexit preparations.

The suspension and scaling back of work is expected to last until 30 June 2019, but a decision will be taken in April 2019 when a full programme of work can resume.

“[The] EMA will now temporarily suspend or scale back additional activities to ensure that resources can be redeployed so that its core activities can continue without interruption and to the same quality,” said Noël Wathion, deputy executive director at the EMA.  

“Over the next few months, [the] EMA will continue to carefully monitor staff intentions to relocate and the anticipated impact on its activities whilst planning for the critical time period when [the EMA] will be moving to its new premises in Amsterdam.”

One of the reasons Amsterdam was chosen as the new home of the EMA  after Brexit was its popularity with staff. But the EMA has since said that it expects to lose around a third of its staff when it leaves its current London headquarters.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205592

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £133.00Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £252.00Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £38.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The EMA's new building in Amsterdam

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.